MedComm · Nov 17, 2026

Advances in 3D‐Printed Scaffolds for Regenerative Therapy

By Song S, Guo N, Wang S et al.

Three‐dimensional (3D) printing enables precise control over scaffold geometry, porosity, material distribution, and spatial delivery of cells and bioactive cues. However, features intended to improve biological fidelity often increase manufacturing complexity, quality‐control demands, and regulatory burden. This review evaluates 3D‐printed scaffolds for regenerative therapy using a design‐to‐translation framework. We compare acellular printing, cell‐laden bioprinting, and hybrid fabrication, and examine how material composition, architecture, mechanics, degradation, gradients, vascularization, innervation, and immune integration determine performance. Evidence is synthesized across cartilage and osteochondral repair, bone, skin, neural, and spinal cord repair, skeletal muscle and soft tissues, and cardiac and vascular regeneration. Current evidence places acellular or minimally bioactive patient‐specific scaffolds closest to clinical adoption, particularly when anatomical conformity and structural support are the dominant requirements. By contrast, living bioprinted constructs remain limited by reproducibility, tissue maturation, safety, storage, release testing, and scalable manufacturing. We therefore propose that scaffold complexity should be matched to a defined biological bottleneck and assessed using endpoints that capture functional repair, interface stability, host integration, and long‐term performance. This framework shifts evaluation beyond printability toward regenerative benefit, manufacturability, and clinically reproducible design.

doi.org/10.1002/mco2.71102Open accessInterventions

AgingResearch.News